Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Epigenetics in multiple myeloma: From mechanisms to therapy
Mohammad Alzrigat, Alba Atienza Párraga, Helena Jernberg‐Wiklund
Seminars in Cancer Biology (2017) Vol. 51, pp. 101-115
Closed Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

Multiple Myeloma: Available Therapies and Causes of Drug Resistance
Vanessa Carla Monteiro Pinto, Rui Bergantim, Hugo R. Caires, et al.
Cancers (2020) Vol. 12, Iss. 2, pp. 407-407
Open Access | Times Cited: 192
Cancer epigenetics: Past, present and future
Jae Eun Lee, Mi‐Young Kim
Seminars in Cancer Biology (2021) Vol. 83, pp. 4-14
Closed Access | Times Cited: 71
Targeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma
Jing Liu, Ying Xie, Jing Guo, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 61
IRF4 in multiple myeloma—Biology, disease and therapeutic target
Alessandro Agnarelli, Tim Chevassut, Erika J. Mancini
Leukemia Research (2018) Vol. 72, pp. 52-58
Open Access | Times Cited: 61
Multiple Myeloma: Challenges Encountered and Future Options for Better Treatment
Srijit Das, Norsham Juliana, Noor Anisah Abu Yazit, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1649-1649
Open Access | Times Cited: 34
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2)
Zonghui Ma, Andrew A. Bolinger, Haiying Chen, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 16, pp. 10991-11026
Open Access | Times Cited: 21
A comprehensive review of the PTEN/PI3K/Akt axis in multiple myeloma: from molecular interactions to potential therapeutic targets
Mina Alimohammadi, Payman Rahimzadeh, Ramin Khorrami, et al.
Pathology - Research and Practice (2024) Vol. 260, pp. 155401-155401
Closed Access | Times Cited: 8
The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies
Taylor Harding, Linda B. Baughn, Shaji Kumar, et al.
Leukemia (2019) Vol. 33, Iss. 4, pp. 863-883
Closed Access | Times Cited: 52
The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response
Eva De Smedt, Hui Lui, Ken Maes, et al.
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 47
A novel circRNA-miRNA-mRNA network revealed exosomal circ-ATP10A as a biomarker for multiple myeloma angiogenesis
Manya Yu, Jie Yu, Yanyu Zhang, et al.
Bioengineered (2021) Vol. 13, Iss. 1, pp. 667-683
Open Access | Times Cited: 40
RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-κB and MAPK signaling pathways
Jianwei Qu, Yifan Hou, Qingxiao Chen, et al.
Oncogene (2021) Vol. 41, Iss. 3, pp. 400-413
Open Access | Times Cited: 39
Cereblon enhancer methylation and IMiD resistance in multiple myeloma
Larissa Haertle, Santiago Barrio, Umair Munawar, et al.
Blood (2021) Vol. 138, Iss. 18, pp. 1721-1726
Open Access | Times Cited: 38
CRISPR/Cas mediated epigenome editing for cancer therapy
Imran Ansari, Animesh Chaturvedi, Deepak Chitkara, et al.
Seminars in Cancer Biology (2021) Vol. 83, pp. 570-583
Closed Access | Times Cited: 34
Emerging concepts on the role of epigenetics in the relationships between nutrition and health
Patrick J. Stover, W. P. T. James, Anna Krook, et al.
Journal of Internal Medicine (2018) Vol. 284, Iss. 1, pp. 37-49
Open Access | Times Cited: 46
Abnormal microRNA expression in the course of hematological malignancies
Agnieszka Szymczyk, Arkadiusz Macheta, Monika Podhorecka
Cancer Management and Research (2018) Vol. Volume 10, pp. 4267-4277
Open Access | Times Cited: 39
An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
Jeffrey R. Sawyer, Erming Tian, Brian A. Walker, et al.
Blood Cancer Journal (2019) Vol. 9, Iss. 8
Open Access | Times Cited: 36
Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
Roberto Ria, Assunta Melaccio, Vito Racanelli, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 6, pp. 1765-1765
Open Access | Times Cited: 33
IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma
Sha Song, Fan Gao, Qi Li, et al.
Oncogene (2021) Vol. 40, Iss. 35, pp. 5393-5402
Closed Access | Times Cited: 31
Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment
Veronika S. Urbán, Andrea Cegledi, Gábor Mikala
GeroScience (2022) Vol. 45, Iss. 2, pp. 727-746
Open Access | Times Cited: 22
Osteoblast suppression in multiple myeloma bone disease
Juraj Adamik, Deborah L. Galson, G. David Roodman
Journal of bone oncology (2018) Vol. 13, pp. 62-70
Open Access | Times Cited: 36
PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma
Tian Xia, Ming Liu, Quan Zhao, et al.
Cell Death and Disease (2021) Vol. 12, Iss. 10
Open Access | Times Cited: 27
HRP2 regulating MICU1-mediated Ca2+ overload to dictate chemoresistance of multiple myeloma
Qian Li, Ziyi Peng, Li Lin, et al.
Neoplasia (2025) Vol. 62, pp. 101150-101150
Closed Access
EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes
Taylor Harding, Jessica Swanson, Brian G. Van Ness
Oncotarget (2018) Vol. 9, Iss. 31, pp. 21930-21942
Open Access | Times Cited: 30
The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
Tina Paradžik, Cecilia Bandini, Elisabetta Mereu, et al.
Cancers (2021) Vol. 13, Iss. 6, pp. 1235-1235
Open Access | Times Cited: 21
The Role of Epigenetics in the Development and Progression of Multiple Myeloma
Nor Hayati Ismail, Ali Mussa, Nur Atikah Zakaria, et al.
Biomedicines (2022) Vol. 10, Iss. 11, pp. 2767-2767
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top